MFN News Items – Page 21

Subscription period for iZafe warrants (series TO 8 B) begins today Friday, December 4

In November 2019 iZafe Group AB (publ) (“iZafe” or “the Company”) carried out a rights issue of units, consisting of shares and series TO 8 B warrants. The subscription period for the series TO 8 B warrants begins on Friday, December 4, 2020 and continues up to and including December 18, 2020.

One (1) series TO 8 B warrant entitles the holder to subscribe for one (1) new Class B share in iZafe. Under the terms of the warrants the exercise price is SEK 3,30. If all the warrants are exercised, iZafe will receive proceeds of around SEK 9,4 million before issue costs.

Summary instructions and important dates

• Warrant holders wishing to exercise these warrants to subscribe for Class B shares must notify this themselves in good time before Friday, December 18, 2020. After this date the warrants will expire and become worthless.

• Holders who do not wish to exercise their warrants are recommended to sell them. The warrants will be traded up to and including Wednesday, December 16, 2020.

Detailed instructions for holders of warrants are given below.

Exercise of warrants held by a nominee
Those whose series TO 8 B warrants are held by a nominee [held in a custodian account, investment savings account (ISK) or endowment policy (KF)] must notify that they wish to exercise warrants by contacting their nominee and following the nominee’s instructions for subscription and payment. This should be done in good time before Wednesday, December 16, 2020, since different nominees have differing processing times.

Exercise of warrants registered in own name
Holders of series TO 8 B warrants that are registered in their own name [holdings in a securities (VP) account] must notify that they wish to exercise warrants by completing and submitting a Notice of Exercise for iZafe’s series TO 8 B warrants so that it is received by the issuing agent Hagberg & Aneborn Fondkommission by 15:00 CET on Friday, December 18, 2020 at latest.

The Notice of Exercise can be downloaded from:

iZafe’s website, www.izafe.se/teckningsoptioner; and

Hagberg & Aneborn Fondkommission’s website, www.hagberganeborn.se

Note that payment for the new shares must also be received by Hagberg & Aneborn Fondkommission by December 18, 2020 at the latest in accordance with the instructions in the Notice of Exercise.

Trading in iZafe series TO 8 B warrants
Holders who do not wish to exercise their warrants are recommended to sell them on First North Premium Growth so that another party can exercise the warrants. The iZafe series TO 8 B warrant is being traded on First North Premium Growth up to and including Wednesday, December 16, 2020. Warrants that are not exercised before December 18, 2020 or sold before December 16, 2020 will expire and become worthless.

Result and delivery of new shares
The result of the exercise of series TO 8 B warrants will be published in a press release on or around Friday, December 18, 2020.

The new shares will be delivered to the subscribers’ accounts as interim shares (IS). They will then be admitted to trading on First North Premium Growth as soon as the issue has been registered with Bolagsverket (the Swedish companies registration office) and Euroclear.

Full terms and conditions for iZafe series TO 8 B
Full terms and conditions for iZafe series TO 8 B are available in the information memorandum prepared by iZafe’s Board of Directors in conjunction with the rights issue in 2019.

The memorandum can be downloaded from iZafe’s website www.izafe.se/teckningsoptioner or be downloaded directly here.

ISIN code
The ISIN code for iZafe series TO 8 B is SE0013409406.

Number of series TO 8 B warrants and potential proceeds
The number of warrants amounts to 2,862,129. If all the warrants are fully exercised, iZafe will receive proceeds of around SEK 9,4 million, before issue costs.

Advisor
Stockholm Corporate Finance AB is acting as financial advisor, KANTER advokatbyrå KB as legal advisor and Hagberg & Aneborn Fondkommission AB as issuing agency in connection with the exercise of the warrants.

About Stockholm Corporate Finance
Stockholm Corporate Finance is an independent privately-owned financial advisor offering expert advisory services relating to capital raising, changes in ownership, and mergers, acquisitions and divestments (M&A) for listed and privately held companies and their owners. Stockholm Corporate Finance is the exclusive Swedish partner in the global network M&A Worldwide, which is comprised of 46 M&A advisors and investment banks in 38 countries. Stockholm Corporate Finance is under the supervision of Finansinspektionen (Sweden’s financial supervisory authority) and is a member of industry organization SwedSec Licensiering AB. For more information see www.stockholmcorp.se/eng/.

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at investor.izafe.se.

Subscription period for iZafe warrants (series TO 8 B) begins today Friday, December 4

Change in the number of shares and votes in iZafe Group AB

The number of shares and votes in iZafe Group AB has changed due to the issue of 93,571 new Class B shares during November in connection with the exercise of warrants issued in November 2018.

Following the exercise of the warrants, the total number of shares in iZafe Group AB is 32,862,081, of which 600,000 are Class A shares and 32,262,081 are Class B shares. The total number of votes is 38,862,081.

About Us

Change in the number of shares and votes in iZafe Group AB

Subscription price determined for iZafe’s warrant TO 8 B

The subscription price for warrant TO 8 B iZafe Group AB (“iZafe” or “the Company”) has been set at SEK 3.30 in accordance with the applicable option terms. One (1) warrant TO 8 B entitles the holder to subscribe for one (1) B share in iZafe. Subscription of Class B shares with the support of warrants can take place from and including 4 December 2020 to and including 18 December 2020. If all warrants of series TO 8 B are exercised, the Company will receive SEK 9,445,000 before issue costs.

Conditions in summary

Subscription period: 4 – 18 December 2020 (subscription takes place through simultaneous cash payment).

Number of warrants: 2,862,129 warrants of series TO 8 B.

Subscription price: The holder of warrants has the right to subscribe for one new B share in iZafe for each warrant at the subscription price of SEK 3.30 per share.

Issue volume: When full exercise of all warrants, SEK 9,445,026 is added to iZafe.

Last day for trading in warrants: 16 December 2020.

About Us

Subscription price determined for iZafe's warrant TO 8 B

Ida Almgren appointed CFO of iZafe Group AB

Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life- Science company focused on health care digitalisation, today announces the appointment of Ida Almgren as the new CFO. Ms Almgren will join the company on 9 November 2020.

Ida Almgren has many years of experience with and responsibility for business analysis and financial planning with established companies. Ms Almgren’s professional experience includes working with high-growth companies and start-ups in various phases of development, where her areas of focus included strategy and growth. Immediately prior to joining iZafe, Ms Almgren served in the role of Revenue Manager for SAS, and was previously the CFO of Thunderkick.

“I bring expertise to iZafe Group acquired through my experience as a CFO and member of executive management teams in roles that entailed overall financial responsibility. I look forward to returning to a smaller, entrepreneurial company where I can be involved in internationalising and further developing the business,” says CFO Ida Almgren, iZafe Group.

About Us

Ida Almgren appointed CFO of iZafe Group AB

iZafe Group signs partnership agreement with Vivago and launches initial joint pilot project

Stockholm, Sverige – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading Life Science company focused on the digitalisation of medication management, is announcing that it has signed a partnership agreement with Vivago, a Finnish provider of safety and well-being solutions for preventive care. In conjunction, iZafe and Vivago are launching an initial joint pilot project covering 20 Dosell medication dispensing robots.

The results of the pilot project will be used as decision input for a future commercial arrangement based on an integrated solution involving automated dispensing of medication in dose-packed sachets from dispensing robots. The goal is to create a full-coverage solution for users while reducing the need for home health visits in connection with taking medication.

“We are proud of the partnership and are looking forward to working with Vivago to further develop the industry in Finland. In the first stage, we will perform a joint market analysis to build knowledge about the Finnish market. We are especially pleased that our partnership has already resulted in a strategically important pilot project.” comments Anders Segerström CEO, iZafe Group.

Major training initiatives were carried out in the autumn to prepare for the pilot project, which is expected to begin immediately after the end of the year. Twenty people will be using Dosell to manage their medication during the pilot project.

“We are delighted by the partnership between Vivago and iZafe. The partnership will be a key step in Vivago’s future ventures in the digitalisation of medication dispensing in Finland while reinforcing our service offering. The partnership with iZafe and their Dosell digital medication dispenser makes a more comprehensive service offering to our customers in Finland possible. Vivago’s health and well-being solutions combined with Dosell will enhance safety and provide better care to our elderly people.” Says Niina Vilkas, CEO Vivago Ltd.

About Vivago
Vivago develops smart safety and wellbeing solutions for preventive care by monitoring users’ health status in real-time and wellbeing 24/7. The Vivago solution includes all features required for nurse call systems and covers the entire chain of care from home care and assisted living to rehabilitation centres and hospitals. More than 100,000 people use Vivago solutions every single day. Full digitalisation of health status monitoring is opening a revolutionary path to changing care delivery from reactive to preventive while tailoring entirely patient-centred and results-driven care.

About Us

iZafe Group signs partnership agreement with Vivago and launches initial joint pilot project

iZafe Group Q3 Interim Report, July-September 2020

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – today November 9, releases its Q3 Interim Report.

Condensed statement of financial performance

Net sales for the quarter totaled SEK 701 thousand (3,344). Sales for the quarter comprise revenue related to the sale of Dosell. In previous years, this item also included revenue attributable to the iZafe Security business area, which was sold.

Operating profit for the quarter totaled SEK 7,255 thousand (-4,028) including one-off effects related to the sale of iZafe AB. Excluding the sale of the Security business area the operating was SEK -6,745 thousand (-4,028).

Operating profit for the quarter totaled SEK 7,103 thousand (-4,130) including one-off effects related to the sale of iZafe AB. Excluding the sale of iZafe Security, earnings after financial items totaled SEK -6,897 thousand (-4,130).

Cash flow for the period was SEK 8,818 thousand (-456), as a result of the payment received for the sale of iZafe AB.

Earnings per share for the quarter, basic and diluted, totaled SEK 0.2 (-0.2).

Equity per share at the end of the period was SEK 1.1 (1.4).

The equity ratio at the end of the period was 87.4 percent (51.7).

Significant events during the year

iZafe Group sold the Security business area, thereby creating a dedicated and financially strong Life Science company focused on the Healthcare business area and the Dosell medication dispensing robot.

Following a successful pilot project in Norway, iZafe’s partner Doro Care AS placed an initial order for 50 medication dispensing robots.

iZafe’s Italian partner has initiated an operational phase at a pharmacy in the Trento region, where equipment that packages medications in sachets has been installed.

A pilot project was initiated with the care service provider Attendo. The goal of the project is to produce documentation for decision-making regarding the potential implementation of the Dosell medication dispensing robot for use in Attendo’s home services business.

A pilot project was initiated with the care service provider TioHundra AB involving 30 medication dispensing robots. The results will provide a basis for identifying areas where welfare technology can contribute to more efficient, safer operations at TioHundra in Norrtälje Municipality, Sweden.

iZafe published a patent application that the company submitted relating to the further development of the Dosell medication dispensing robot. The application is international and will enable iZafe Group to have patents approved in over 150 countries.

Comments by the CEO

At the beginning of the quarter the sale of iZafe Security closed successfully, thereby freeing up the resources needed to accelerate commercialization and globalization of the Dosell medication dispensing robot. The sale was carried out after the iZafe Group Board of Directors conducted an evaluation to determine how the current organization and product offering could ultimately result in profitability and a return on investment. Together with management, we concluded that iZafe should become a dedicated Life Science company, for which reason the decision to sell the safety and security business was a logical step in the process.

A dedicated Life Science company based on Dosell has the best prospects for growth. Through future investments in the product and market, combined with an organization that focuses solely on one business area, we become a strong participant on a rapidly growing market in Sweden and abroad.

I am pleased with the way that we have maintained our close contacts with customers and partners despite the coronavirus pandemic and interest in Dosell and our technology has increased as a growing number of decision-makers and opinion leaders have recognized the importance of digitalization within health services and elderly care. However, like most other participants in the market, we have noted that purchasing decisions and deployment have taken longer since health services and society have been forced to prioritize where time should be spent. Globalization has its challenges in that we have not been able to visit new markets in person. Net sales for the quarter totaled SEK 701 thousand (3,344), relating exclusively to revenue attributable to Dosell. The corresponding period last year also included revenue attributable to the iZafe Security business area, which was sold. Operating profit for the period totaled SEK 7,255 thousand (loss: -4,028) including the one-off effect related to the sale of iZafe Security. Excluding the sale, the operating loss was SEK -6,745 thousand (loss: -4,028).

Our business with our Norwegian partners has continued according to plan and we have seen favorable commercial development for Dosell in Norway. We have completed the validation of sachets in Finland and look forward to the upcoming first pilot project. On the Swedish market, an important milestone was achieved when we launched pilot projects with care service providers Attendo and TioHundra. The projects enable us to demonstrate the possibilities that Dosell represents regarding facilitating and creating safer medicine dispensing within the home help services and personal assistance business area in Sweden.

Collaboration within the framework of the Sempli Farma project in Italy has increased sharply after the total lockdown that Italy imposed last spring. Marketing of the concept has begun with Dosell occupying a prominent position. We look forward to the developments in Italy with great excitement and we can conclude that the consumer version of Dosell that is being launched there also has great potential in other markets. We have also noticed strong interest in Dosell from other countries, especially the UK and Germany.

After the end of the quarter a submitted patent application relating to further development of Dosell was published, which will enable us to achieve our ambition to create a healthcare setting at home through Dosell and the Dosell app.

Given current trends in society and our strong position, I am confident that we will be able to continue to launch and commercialize Dosell in our markets.

About Us

IZafe Group AB Q3 Quarterly Report 2020

With the release of the quarterly report, iZafe will present a Q&A session with video

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading Life Science company specializing in healthcare services digitalization announces the opportunity for shareholders, media, and other stakeholders to ask company-related questions in connection with its Third Quarter 2020 report. The report will be available to the public on on November 9, 2020 at 08.30 (8:30 a.m.) CET. Questions will be answered by Chief Executive Officer Anders Segerström in a video presentation that will be published on November 18, 2020 on iZafe's website under the heading Investor Relations.

Please send your questions to before 17:00 (5 p.m.) CET on November 10, 2020. You can also use an online form to send your questions. This form is available on iZafe's website, Investor Relations page.

About Us

With the release of the quarterly report, iZafe will present a Q&A session with video

Publication of patent application strengthens iZafe Group’s grip on the digitalization of home care

Stockholm, Sweden. iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) (“the company”) reports that a patent application filed by the company has been published. The patent relates to a further development of the medication management robot Dosell, enabling Dosell and the Dosell app to become a hub for connected sensors and other digital care equipment in the home collection and measureing patient-specific data. The patent application is international and enables iZafe to have patents approved in more than 150 countries.

The current patent application could provide the company with future patents in a large number of countries including Sweden, other parts of Europe and the USA. The fact that iZafe has a patent pending already in itself affords important protection for the company’s further development of Dosell as a digital platform and additionally strengthens iZafe’s position in the market.

“The digitalization of healthcare has accelerated in recent years, and iZafe is a leading provider of medication dose dispensing for those who want to manage their medication themselves. By protecting the further development of Dosell into a digital hub for a future digital clinic in the home, we are strengthening our position as well as our patent portfolio,” says Anders Segerström, CEO of iZafe Group.

The patent application relates to the development of a system for dispensing medication via the Dosell robot in which the dose of medication dispensed is adjusted based on current patient-specific information.

“We are convinced that the ecosystem that Dosell provides via medication dispensing and the SaaS-based services is just the start of a rapid digitalization of many measurements that can be monitored by the doctor responsible for the patient via the Dosell app. The fact that we now have a patent pending in this area is an important part of our long-term strategy for positioning iZafe as a leading player in the digitalization of home and remote healthcare. Publication of the patent application that was filed 18 months ago strengthens our position in the market while also protecting us from competitors,” says Anders Segerström.

Future digital care in the home
We are living longer and longer, and an aging population increases the need for care and social services. Society aims to deliver increasing quality for our seniors and an important part of this ambition is to offer an increasing level of care in the home. iZafe’s vision of a “digital clinic in the home” will only be possible if important information about the patient’s state of health can be measured and communicated to the treating doctor.

This further development of Dosell allows sensors in the home to take the patient’s readings and communicate these via iZafe’s cloud-based solution. The treating doctor can then make sure that the correctly adjusted dose is always given to the patient via Dosell. The new technology further increases patient safety in respect of the dosing and dispensing of medication. Using Dosell as a hub realizes the vision of a digital doctor’s round in the home, which will be particularly important for patients being treated for conditions such as dementia, complex heart problems, diabetes, Parkinson’s and MS.

“Through Dosell, iZafe has already set a new standard for digital medication dispensing and future patents will enable the company to revolutionize care – above all in the home and especially for seniors, people with multiple conditions and patients on multiple medications,” says Dr Göran Sjönell, doctor in general medical practice, co-founder of iZafe Group and inventor of Dosell.

About Us

Publication of patent application strengthens iZafe Group’s grip on the digitalization of home care

iZafe and healthcare company TioHundra start pilot project with medication dispensing robot Dosell

Stockholm, Sweden. iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading life science company in the digitalization of medication management – has announced the start of a pilot project with healthcare company TioHundra AB involving 30 medication dispensing robots. The results will provide a basis for identifying areas where welfare technology can contribute to more efficient, safer operations at TioHundra in Norrtälje municipality, Sweden.

During the pilot project TioHundra and iZafe aim to identify, prioritize and work to enable operational developments in Norrtälje municipality. TioHundra’s ambition is to introduce the technology that Dosell represents to facilitate and create safer medication distribution within the area of home care services and personal assistance.

“Using Dosell will enable TioHundra to ease the burden on its employees, because medication dispensing robots increase safety and can save both time and resources. Dosell can also simplify coordination of functions for company medication signing to avoid duplicate records. A crucial advantage of Dosell is that it makes life safer for users, allowing them to live an independent life in their own home for longer with less risk of medication errors. Relatives also benefit from increased security thanks to the function for remote monitoring,” says Anders Segerström, CEO of iZafe.

About the pilot project
TioHundra’s aim for the pilot project is to allow patients/users to manage their medication themselves, thereby increasing their independence. Digital tools such as medication dispensing robots are classed as welfare technology and provide important support for ensuring safe medication management, which is currently managed manually. Care professionals in Norrtälje must travel significant distances daily, with many patients needing more than one visit a day, to dispense medication and provide other minor assistance. TioHundra hopes to use digital tools to streamline its operations, so that it can make fewer visits and improve the quality of those visits instead.

The trial period with Dosell will provide a basis for TioHundra’s decision on whether to purchase medication dispensing robots.

About TioHundra AB
TioHundra is unique in Sweden in that it is the only company offering a full range of health care and social care services. TioHundra’s innovative and efficient approach improves the quality of care and creates added value for patients, users, those close to them and employees. The Norrtälje model has attracted attention both regionally and internationally, being held up by Sweden’s Ministry of Health and Social Affairs as an example to other municipalities, county councils and regions.

About the medication dispensing robot Dosell
Dosell is a robot that manages the dispensing of medication sachets. The roll of sachets is installed in the robot and programmed by healthcare personnel. The medication is then dispensed by the robot at the times printed on the sachets. The sachet is cut open when it is dispensed, and the patient then takes their medication independently. A reminder function helps patients to remember to take their medications. If the patient does not take the sachet despite the reminder, an app sends an alert to healthcare professionals who can then make a home visit to ensure the medication is taken.

About Us

iZafe and healthcare company TioHundra start pilot project with medication dispensing robot Dosell

Dosell medication dispensing robot

iZafe och Attendo inleder pilotprojekt för säkrare läkemedelshantering

Stockholm, Sverige – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – ett ledande Life-Science bolag inom digitalisering av läkemedelshantering meddelar att man inleder ett pilotprojekt med omsorgsbolaget Attendo. Målsättningen med projektet är att ta fram beslutsunderlag för ett potentiellt införande av läkemedelsroboten Dosell i Attendos hemtjänstverksamhet.

Attendo Sverige har tillsammans med iZafe identifierat Attendos hemtjänstverksamheter i Uppsala och Norrtälje som lämpliga för att genomföra pilotprojektet, då dessa verksamheter har sjuksköterskor med rätt erfarenhet.

”iZafe fokuserar på patientsäkerhet och digitalisering av vården och med det här pilotprojektet utvärderas effekterna för Attendo och de kunder som de ansvarar för. Dosell är ett viktigt hjälpmedel som kan bidra till en tryggare vardag för kunder med målsättningen att förebygga och minimera felmedicinering.” säger Anders Segerström, VD iZafe Group.

iZafe ansvarar för nödvändig utbildning av ansvariga sjuksköterskor och av deltagande medarbetare på respektive hemtjänstverksamhet. Pilotprojektet pågår under två månader med läkemedelsrobotar som placeras i kundernas hem. Under testperioden kommer Attendo pröva nyttan av att använda iZafes teknik i hemtjänstverksamheten.

Syftet med projektet är att utreda följande frågeställningar:

Finns det kundkategorier i hemtjänstverksamheten som skulle vara hjälpta av produkten?
Kan produkten integreras i befintliga system?
Går det att använda produkten på ett patient- och läkemedelssäkert sätt?
Finns det risker i användandet kopplat till specifika patientkategorier?

Om Attendo AB
Attendo AB är ett börsnoterat svenskt företag som erbjuder tjänster inom äldreomsorg, omsorg till personer med funktionsnedsättning samt individ- och familjeomsorg. Företaget bedriver även verksamhet i Finland och Danmark.

Om läkemedelsroboten Dosell
Dosell är en läkemedelsrobot som hanterar dospåsar. Dosrullen installeras i roboten och programmeras av personal. Läkemedlen administreras därefter ut i roboten på angivna tidpunkter på dospåsen. Dospåsen klipps i samband med administrationen upp och patienten tar sedan sin medicin självständigt. En påminnelsefunktion underlättar för patienten att komma ihåg att ta sin läkemedelsdos. I de fall patienten trots påminnelsen inte tar sin dospåse skickas ett larm ut via en applikation till personal som då kan göra ett hembesök för att säkerställa läkemedelsdistributionen.

Om iZafe Group AB (publ)

iZafe Group är ett renodlat Life-Science företag som leder utvecklingen av digital läkemedelsdispensering. Bolaget bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet. iZafes läkemedelsrobot Dosell används för att minska risken för felmedicinering i hemmet, avlasta den offentliga vården, öka livskvaliteten för patienten samt skapa en tryggare miljö för anhöriga. Kunderna utgörs idag av offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

Bolaget är noterat på NASDAQ First North Premier Growth Market. FNCA Sweden AB är bolagets Certified Adviser. Telefon: +46 (0) 8 528 00 399. E-post: . Ytterligare information finns på investor.izafe.se.

iZafe och Attendo inleder pilotprojekt för säkrare läkemedelshantering